Viusid

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Viusid

What is Viusid? Identity and Classification

Property Description
Active components Vitamins (C, B6, B12), Arginine, Zinc, Glycyrrhizic Acid
Form Oral powder for solution
Pharmacological class Nutraceutical, complex Dietary Supplement
General Purpose Support for Immune and Metabolic functions
Origin Mixed Synthetic-derived and Naturally-derived components

Viusid is precisely defined as a specialized Nutraceutical and complex Dietary Supplement, formulated as an oral powder for solution. This multi-component formulation provides support for the body’s Immune System and essential nutritional replenishment. Unlike traditional prescriptive drugs, Viusid's identity is anchored in providing comprehensive metabolic support, a function that is clinically recognized for preparations targeting nutritional imbalances. Its distinction lies in its powder form, which is intended to be bioavailable via the oral route of administration.


Composition: Essential Components and Origin

The core composition of Viusid is a comprehensive matrix featuring several essential Vitamins, specific Amino Acids such as Arginine, Glucosamine, and Glycine, and the crucial trace Mineral Zinc (as Zinc Sulfate, ZnSO4). Further differentiating this preparation is the presence of Glycyrrhizic Acid, the main active compound of liquorice root, and Honey as excipients. The inclusion of Zinc is a key element of the formulation. The preparation is thus a mixed-profile product, combining essential synthetic-derived nutrients with naturally-derived compounds.


General Purpose: Support for Immune and Metabolic Functions

The general purpose of Viusid is to provide foundational physiological support, primarily through Antioxidant and Immunomodulatory effects. A typical neutral use scenario involves individuals seeking support for their general well-being during periods of Immunodeficiency states or when managing pronounced Nutritional deficiencies. The systemic effect is further supported by the presence of Glycyrrhizic Acid, noted for its supportive properties and its immunomodulatory potential in specific cell lines. By delivering these synergistic compounds, the preparation aims to bolster the body's general resilience and metabolic integrity.

What side effects are possible with Viusid?

Possible Side Effects and Safety Information

The safety profile for Viusid, a complex dietary supplement, is primarily characterized by general statements on tolerance and specific constraints derived from authoritative regulatory and clinical trial sources.

Officially Documented Adverse Reactions

Adverse events reported in clinical evaluations have generally been described as mild and short-lived. Officially documented safety data, which is less comprehensive than for prescription pharmaceuticals, has not listed a broad spectrum of side effects.

Classification Detail
System-Organ Classes Gastrointestinal Disorders (Implied by documented effects)
Common Side Effects Adverse reactions were typically mild and transient.
Serious Reactions None explicitly documented as serious (Grade 3 or 4) or fatal in regulatory-aligned sources.
Frequency Categories Standard regulatory frequency terms (e.g., Very Common, Rare) are not formally applied in public safety data.

Safety Constraints and Restrictions

The safety profile establishes specific limitations for its use, based on patient characteristics and clinical study exclusion criteria:

  • Known Hypersensitivity: The preparation is constrained for use in individuals with known hypersensitivity or allergy to any of the active components (Vitamins, Amino Acids, Zinc, Glycyrrhizic Acid) or excipients.
  • Underlying Organ Conditions: Use is restricted in individuals with specific severe underlying conditions. Clinical trial protocols have excluded patients with severe liver disease (e.g., decompensated cirrhosis) and certain severe chronic kidney diseases, reflecting caution in these populations.

This information strictly outlines the risk and limitation profile as established by official sources, without incorporating information on dosing, usage, or therapeutic benefits.

Overdose and Emergency Response

The official regulatory profile for excessive intake of Viusid's components is defined by several distinct toxicity patterns. Overdose manifestations include severe electrolyte disturbances, such as Hypokalemia, which can lead to life-threatening Cardiac Arrhythmia and Acute Renal Failure. Other documented symptoms involve Hypertension and generalized Muscle weakness. Acute, excessive ingestion may cause severe gastrointestinal distress, including Vomiting, Bloody diarrhea, and a distinctive Metallic taste, associated with high-dose zinc. Chronic high-dose exposure is officially linked to Peripheral sensory neuropathy, characterized by numbness and tingling sensations.

When to Seek Help

Immediate medical attention must be sought upon suspicion of severe component overdose, particularly if experiencing an irregular heart rhythm or sudden, pronounced muscle weakness. Regulator-mandated action requires stopping the product immediately if persistent neurological symptoms like tingling or numbness occur. The official management involves symptomatic and supportive treatment, which may include continuous hospital monitoring, Potassium replacement, and specific procedural steps such as Gastric lavage or the use of Chelating Agents for severe zinc toxicity. Increased risk of severe cardiac effects is noted for adults over 40 and individuals with pre-existing hypertension.

Therapeutic Uses of Viusid

Viusid is a complex dietary supplement. It is applied across domains where additional symptomatic support is needed, particularly in the context of chronic and acute physiological stress. This preparation is utilized in situations involving symptoms linked to organ-specific functional stress.


Supportive Care for Chronic Liver and Kidney Conditions

This preparation is commonly used as an adjunctive measure to support patients managing conditions characterized by periods of heightened symptoms such as decompensated cirrhosis or Chronic Kidney Disease (CKD) Stage 5 on haemodialysis. It may offer supportive benefits that contribute to improved day-to-day comfort and supports patients in managing long-term conditions. It is used in areas where short-term symptom management is appropriate, particularly across conditions presenting with systemic or localized discomfort.

Management of Systemic Fatigue and High-Stress Contexts

Viusid is commonly used to help with symptoms related to physical discomfort, such as fatigue and lack of energy, commonly linked to chronic illness. It is relevant in clinical settings that involve acute or unstable symptom patterns, such as when patients are managing certain advanced conditions. It supports the patient during difficult episodes by easing distress and assists with maintaining a sense of stability, which may help patients cope more steadily with challenging symptomatic episodes.

Quick Fact: Relief for Systemic Fatigue

Viusid is commonly used to help with symptoms related to energy depletion, supporting patients during symptomatic phases where fatigue interferes with routine activities.

Eligibility and Restrictions for Use

Who Can and Cannot Use Viusid?

The eligibility profile for Viusid is strictly defined by the exclusion criteria documented in government-registered clinical trials, which establish the populations for whom use is contraindicated or restricted under clinical supervision.


Eligibility Scope

Population Status Eligibility Criteria as per Regulatory Sources
Populations Allowed Adults and Older Adults (established for individuals mathbf18 years and older).
Populations Contraindicated Pregnant patients and lactating patients must not use this product. Contraindicated in individuals with a known hypersensitivity to any component.
Age-Related Rules Use is not established in the pediatric population (individuals under 18 years), based on the minimum age thresholds defined in official studies.
Condition-Based Rules Use is contraindicated in patients with decompensated intercurrent diseases, including unstable cardiac arrhythmia, active infections, and severe liver damage. Eligibility is restricted if specific laboratory parameters (e.g., Creatinine or Bilirubin) are outside established limits.
Co-treatment Restriction Use is not recommended for patients concurrently receiving other antioxidant supplements.

Eligibility Classifications

Classification Type Status Defined by Official Documents
Severity Classification Contraindicated (Absolute), Use Not Established (Pediatric), Restricted Use (Conditional).
Regulatory Basis The criteria are derived from official NIH ClinicalTrials.gov exclusion lists.

Connection to the overall eligibility profile: Official regulatory documentation defines eligibility by formally excluding high-risk groups, such as pregnant or lactating individuals, and those presenting with unstable or decompensated severe systemic diseases. This framework formally dictates that use is established only for the adult population that meets specific criteria for physiological stability.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Viusid is established based on the regulatory analysis of its active components, primarily Glycyrrhizic Acid. This profile details clinically relevant pharmacokinetic and pharmacodynamic interactions with specific drug classes.

Pharmacodynamic Interactions

Co-administration with medicinal products that cause potassium loss, such as certain diuretics, is officially restricted due to a heightened and potentially severe risk of hypokalemia. The preparation may also potentiate the effects of corticosteroids by reducing their metabolism, an interaction that may increase mineralocorticoid-like effects. Because of the risk of hypokalemia, there is a documented increase in the risk of toxicity when combined with Digoxin.

Pharmacokinetic and Efficacy Alterations

The Glycyrrhizic Acid component may alter the plasma concentration of co-administered medicines that are substrates for specific metabolic enzymes, including CYP3A4 and CYP2C9, and the efflux transporter P-glycoprotein. This pharmacokinetic modification may influence the systemic exposure of these substrates. Furthermore, official documentation notes that regular consumption may reduce the therapeutic efficacy of Antihypertensive medicines and can decrease the effect of the anticoagulant Warfarin.

Restrictions and Constraints

Patients taking potassium-depleting medicines are formally advised by regulatory authorities to avoid regular consumption. The sensitivity to interaction effects related to blood pressure and potassium is documented as increased in populations with pre-existing hypertension and advanced age.

Mechanism of Action

Modulation of NF-kappaB Signaling

The core mechanism involves the Glycyrrhizic Acid metabolite ( 18beta -Glycyrrhetinic Acid), which functions as an inhibitor of the NF-kappaB transcription factor. NF-kappaB is a molecular switch that triggers the gene expression of numerous pro-inflammatory cytokines (e.g., TNF-alpha, IL-6). By intervening in this molecular cascade, the preparation functions to downregulate the signaling drive, leading to reduced expression of inflammatory mediators.

Substrate and Cofactor Supply for Immune Function

This mechanism provides metabolic resources, primarily L-Arginine and Zinc, to support the functional capacity of immune cells. L-Arginine acts as the direct precursor for Nitric Oxide (NO) synthesis via the iNOS enzyme to execute cellular effector functions. Zinc and B vitamins act as crucial cofactors, stabilizing enzymes and transcription factors required for lymphocyte proliferation and function. This contributes to the metabolic readiness of the immune system for activation.

Reduction of Systemic Oxidative Load

This domain is defined by the direct antioxidant activity of Vitamin C, Zinc, and other active components. Vitamin C acts as a potent electron donor, directly scavenging damaging Reactive Oxygen Species (ROS). By reducing the overall oxidative load, the mechanism contributes to the protection of the functional integrity of immune cell membranes and signaling pathways, reducing oxidative cellular stress.

Dosage and Administration Information

The administration of Viusid follows specific usage patterns, consistent with its classification as an oral nutraceutical and dietary supplement.


Administration Route and Preparation

Viusid is designed for oral administration only and is available as an oral powder for solution (sachets) or a pre-prepared oral solution. The powder form requires the contents of the sachet to be dissolved completely in a liquid, such as water or juice, prior to ingestion.

Standard Regimen and Frequency

The standard adult regimen specifies that the total daily dose is divided into three equal portions, administered three times per day (TID). For the liquid solution, this corresponds to 30 mL per dose (90 mL total daily). Administration is routinely aligned with the main meals (breakfast, lunch, and dinner).

Duration and Population Rules

Dosage adjustments are defined for pediatric use, with children from three years of age following a reduced schedule of typically two sachets daily or 5 mL of the solution administered three times per day. Usage duration is structured into distinct patterns: general use is typically limited to a maximum of 6 weeks. However, specific applications have followed extended courses for periods up to 96 weeks. In all cases, the maximum daily dosage specified for the preparation must not be exceeded.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Viusid

Overview of Study Landscape

Research into Viusid includes several types of clinical evaluations, primarily focusing on its evaluation as an additional measure in specific conditions. The research includes Randomized Controlled Trials (RCTs), a study type often used to compare outcomes, where participants are assigned to receive either the product or a comparison (like a placebo or standard care) to observe differences in measured outcomes. Other research includes controlled studies and observational settings. These studies help to show what has been observed so far in defined patient groups under specific conditions, contributing to the broader evidence landscape.

Evidence for Use in Advanced Chronic Liver Disease

Research has explored Viusid was evaluated as an additional substance in adults with significant liver impairment, specifically in conditions like decompensated cirrhosis linked to chronic hepatitis C (HCV). Studies conducted during periods of increased symptom activity explored long-term clinical endpoints. Researchers observed outcomes such as overall survival and the time until significant disease progression events, including the development of liver cancer (Hepatocellular Carcinoma).

Evidence for Use in Nonalcoholic Fatty Liver Disease (NAFLD)

Viusid was explored in studies that administered it alongside standard lifestyle changes in specific patient groups with NAFLD, including Nonalcoholic Steatohepatitis (NASH). Research examined outcomes related to specific measurements by researchers, including histological markers of liver health, such as scores for fat accumulation (steatosis) and inflammation. The research highlights changes measured during the short-term study period, typically over a six-month interval.

What is Still Uncertain About Viusid Research

Research provides context but not individual predictions, and findings describe group patterns, not personal outcomes. Certainty remains low across many indications. Many studies have modest sample sizes and follow-up durations were limited, particularly in the areas of chronic fatigue and immune support, which contributes to the limitations of the evidence. The high variability in study populations also means that overall consistency across the research base is low, and data for certain groups remain insufficient.

Key Studies & References

  1. Viusid, a nutritional supplement, increases survival and reduces disease progression in HCV-related decompensated cirrhosis: a randomised and controlled trial
  2. Viusid/Alzer efficacy in the treatment of Parkinson's disease associated fatigue
  3. Glycyrrhizin (Glycyrrhizic Acid)—Pharmacological Applications and Associated Molecular Mechanisms

Frequently Asked Questions (FAQ)

Common questions about Viusid (FAQ)

Q: Is Viusid considered a drug or a dietary supplement in most countries?

Official governmental registration records and clinical trial documentation generally classify Viusid as a Nutraceutical and complex Dietary Supplement. This classification typically means it is regulated as a nutritional support product rather than a conventional pharmaceutical prescription drug.


Q: Does Viusid have a known risk of causing high blood pressure?

Due to its Glycyrrhizic Acid content, regulatory constraints note that Viusid may reduce the therapeutic efficacy of Antihypertensive medicines. Official warnings also indicate that sensitivity to interaction effects related to blood pressure is documented as increased in populations with pre-existing hypertension.


Q: Does Viusid contain any common allergens like gluten, dairy, or soy?

Official product information does not explicitly list common allergens such as gluten, dairy, or soy. However, the preparation is formally constrained for use in individuals with a known hypersensitivity or allergy to any of its active components (Vitamins, Amino Acids, Zinc, Glycyrrhizic Acid) or any excipients.


Q: Are the reported side effects for Viusid generally considered mild or temporary?

Official safety data indicates that adverse events reported in clinical evaluations have generally been described as mild and short-lived. Furthermore, no serious (Grade 3 or 4) or fatal reactions have been explicitly documented in regulatory-aligned safety reports.


Q: Is there a different formulation of Viusid for children compared to adults?

Official documentation specifies that Viusid is available as both an oral powder for solution and a pre-prepared oral solution. While children's recommended dosage is different, the regulatory texts do not confirm a difference in the overall composition or formulation compared to the adult version.


Q: Why is glycyrrhizinic acid sometimes mentioned as a component in Viusid?

Glycyrrhizic Acid, derived from licorice root, is a core component because its metabolite functions as an inhibitor of the NF-kappaB transcription factor. This mechanism is key to the product's function, as it is understood to help downregulate the signaling drive of pro-inflammatory cytokines (immune cell messengers).


Q: Is Viusid used only for certain specific conditions, or is it for general health support?

The general purpose is defined as providing foundational physiological support through Antioxidant and Immunomodulatory effects. A typical use scenario involves support during periods of Immunodeficiency states or pronounced Nutritional deficiencies, in addition to the specific liver conditions explored in clinical research.


Q: What does 'immunomodulatory properties' mean when referring to Viusid?

Immunomodulatory properties refer to the way the preparation supports the functional capacity of immune cells. This is achieved by supplying metabolic resources and helping to downregulate the signaling drive of pro-inflammatory cytokines, which aims to support the body's general resilience and metabolic integrity.


Q: Is it normal to feel mild digestive upset when first taking Viusid?

Official safety data indicates that adverse events were generally mild and transient. While the official adverse reaction lists imply potential Gastrointestinal Disorders as a system-organ class, they do not specifically categorize or confirm 'mild digestive upset' as a formally documented common symptom.


Q: Are there any known concerns about long-term use of Viusid?

The standard regimen for general, unsupervised use is typically limited to a maximum of six weeks. This limitation is generally associated with the Glycyrrhizic Acid component, which, when consumed for extended periods, carries a documented risk of effects such as potassium loss (hypokalemia).


Q: Does taking Viusid require any special diet or lifestyle changes to be effective?

Official product information routinely aligns administration with main meals but does not mandate specific diet or lifestyle changes for the preparation to be effective. Research has studied its use alongside standard lifestyle changes (such as in NAFLD), but the text does not define these as requirements.


Q: Is there research evidence suggesting Viusid may help with fatigue or overall energy levels?

While the preparation provides metabolic support, official evidence overviews note that specific data for certain groups, including those related to chronic fatigue and immune support, remain insufficient and highly variable. Research has predominantly focused on specific conditions like chronic liver disease.


Q: Can Viusid be taken by people who are vegetarian or vegan?

The composition lists Honey as an excipient in the preparation. While regulatory sources do not provide a definitive statement on suitability for vegetarian or vegan diets, the presence of honey may be a consideration.


Q: Does Viusid come in different forms, such as powder, capsule, or liquid?

Official documents define Viusid as being available in two primary forms: an oral powder for solution (sachets) and a pre-prepared oral solution (liquid). The official documents do not mention a capsule form.


Q: What is the shelf life of Viusid, and how should it typically be stored?

The official instructions mandate that Viusid be stored at room temperature, in a secure location protected from excessive heat, moisture, or direct sunlight. Product registration data typically indicates a shelf life of around 24 months from the date of manufacture.


Q: Does Viusid contain sugar or artificial sweeteners that I should be aware of?

Official composition information lists ingredients including Honey and the artificial sweetener Sucralose. Individuals with diabetes or those monitoring sugar/sweetener intake are encouraged to review the full excipient list.


Q: Do health regulatory bodies in major countries classify Viusid in the same way?

Viusid is consistently classified as a Nutraceutical and complex Dietary Supplement in official documents related to clinical trial registration and product registration in various countries. This classification places it outside the traditional prescription drug category.


Q: Has Viusid been studied for use in specific viral infections?

Research has been conducted in conditions that involve viral causes, such as chronic hepatitis C (HCV). Additionally, Glycyrrhizic Acid, a core component, is a compound recognized in scientific literature for its properties against certain viruses.


Q: Is it true that Viusid is also used in veterinary medicine for animals?

Yes, official product information in some regions confirms that Viusid is also formulated and registered for use in veterinary medicine for certain species, including dogs and cats.


Q: If a person is taking multiple supplements, is it safe to add Viusid to the routine?

Official regulatory documents caution that use is not recommended for patients concurrently receiving other antioxidant supplements. This is due to Viusid’s own antioxidant components, such as Zinc and Vitamin C.


Q: Why does the packaging sometimes suggest limited duration of use?

The typical limitation of use to a maximum of six weeks for general, unsupervised consumption is related to the presence of Glycyrrhizic Acid. This limitation exists to mitigate the potential for issues such as potassium loss (hypokalemia) that may be associated with prolonged intake.


Q: Can Viusid be dissolved in liquids other than water, like milk or juice?

The official instructions for the powder form state that the contents of the sachet should be dissolved completely in a liquid, such as water or juice, prior to ingestion.


Q: Is the licorice extract component a concern for people with kidney issues?

Clinical trial protocols and safety constraints indicate caution in this population, with patients with certain severe chronic kidney diseases being formally excluded. This caution is generally related to the effects of the Glycyrrhizic Acid component.


Q: Do studies suggest Viusid has an impact on inflammatory markers in the body?

The preparation’s mechanism of action involves the Glycyrrhizic Acid metabolite acting to downregulate the signaling drive of pro-inflammatory cytokines. Research overviews also note that studies have examined histological and biochemical markers related to inflammation and steatosis in conditions like Nonalcoholic Fatty Liver Disease (NAFLD).


Q: Does Viusid have a strong or unpleasant taste when dissolved?

The composition lists Lemon Flavouring as an excipient to enhance palatability. The preparation is intended to be fully dissolved in a liquid, such as water or juice, to facilitate comfortable oral ingestion.


Q: Is Viusid safe for people with diabetes due to its composition?

The preparation contains Honey and the sweetener Sucralose. Individuals with diabetes are advised to carefully review the full list of ingredients with a healthcare provider due to the presence of these components.


Q: Is there official information about overdosing on Viusid?

Regulatory guidance requires that the maximum daily dosage specified for the preparation is not exceeded. However, specific, publicly documented information regarding the symptoms or management of an overdose is not available in standard official sources.

How should Viusid be stored and disposed of?

Storage Conditions

Viusid must be stored at room temperature, in alignment with best practices for oral powder formulations. Storage instructions mandate placing the product in a secure location that protects it from specific environmental factors. The product must not be exposed to excessive heat, moisture, or direct sunlight, as these conditions can compromise the stability of the contents.

Child Safety and Disposal

A critical storage requirement is to keep Viusid strictly out of the reach of children and pets to prevent accidental ingestion. Concerning disposal, any unused or expired portions of Viusid must not be discarded in household trash or poured down the drain. Instead, the product should be returned to a pharmacy or designated collection point for proper pharmaceutical waste handling, ensuring safe and regulated disposition.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Viusid found in:

A-Z Index: